Company intelligence / Profile preview

Beijing Houshen Weikang Technology

Beijing, Beijing Shi, Chinaremebot.com.cn ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead program, WS‑0101, has entered early phase clinical trials to evaluate safety and tolerability in healthy adults after topical application for warts. The study also assesses pharmacokinetics and the safety of a semiconductor laser therapy device. No published efficacy results yet.

Therapeutic areas: OncologyDermatologyInfectious Diseases
Modalities: Small molecule (Chemical drugs)Device (Semiconductor laser therapy device)
Industry: Biotech

Beyond the preview

Go deeper on Beijing Houshen Weikang Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Houshen Weikang Technology.

Explore the full profile